Live respiratory syncytial virus vaccine D46/cp/ΔM2-2 is overattenuated in RSV-seronegative children

Clicks: 31
ID: 322757
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #66 of 321 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 321 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but over-attenuated in 12 to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6 to 24-month-old RSV-seronegative children (dose: 105 PFU).
Reference Key
openalex_W7171689376 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ruth A. Karron, Suzanne Woods, Kimberli Wanionek, Jennifer Oliva, Lijuan Yang, Cindy Luongo, Peter L. Collins, Ursula J. Buchholz
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag388
URL
https://doi.org/10.1093/ofid/ofag388
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.